Hard Brexit ‘would mean increased medicine costs’

Patients will have to bear the cost of increased administrative fees for medicines in the event of a hard Brexit, a body representing the sector has said.

Medicines for Ireland, a body with the country’s largest suppliers of medicines to the HSE, said Brexit could have severe monetary as well as social costs.

Joint chair of the body, and general manager of Teva Pharmaceuticals Ireland, Sandra Gannon will speak at a health products Brexit stakeholder event today, where she will outline what the group calls “the risk to patients and to the pharmaceutical manufacturing industry” if a hard Brexit occurs.